Survey: Drugmakers appear to be shifting focus

01/20/2010 | MSNBC

A survey by Tufts University found that the number of treatments that received orphan-drug designation from the FDA increased from 208 products between 2000 and 2002 to 425 between 2006 and 2008. The data highlight pharmaceutical companies' growing interest in drugs for rare diseases, according to the study.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC